{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:14Z","timestamp":1792785014476,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Acibadem Healthcare Group"},{"name":"TUBITAK-BIDEB 2244-University-Industry PhD program","award":["118C082"],"award-info":[{"award-number":["118C082"]}]},{"name":"TUBITAK-BIDEB 2244-University-Industry PhD program","award":["118C082"],"award-info":[{"award-number":["118C082"]}]},{"name":"TUBITAK 2247-C Trainee Researcher Scholarship Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The SARS-CoV-2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma-irradiated inactivated virus vaccine does not require an extra purification process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG-38.61.3) is that it is a non-adjuvant added, gamma-irradiated, and intradermally applied inactive viral vaccine. Efficiency and safety dose (either 10\n                    <jats:sup>13<\/jats:sup>\n                    or 10\n                    <jats:sup>14<\/jats:sup>\n                    viral RNA copy per dose) of OZG-38.61.3 was initially determined in BALB\/c mice. This was followed by testing the immunogenicity and protective efficacy of the vaccine. Human ACE2-encoding transgenic mice were immunized and then infected with the SARS-CoV-2 virus for the challenge test. This study shows that vaccinated mice have lowered SARS-CoV-2 viral RNA copy numbers\u00a0both in oropharyngeal specimens\u00a0and in\u00a0the histological analysis of the lung tissues\u00a0along with humoral and cellular immune responses, including the neutralizing antibodies similar to those shown in BALB\/c mice without substantial toxicity. Subsequently, plans are being made for the commencement of Phase 1 clinical trial of the OZG-38.61.3 vaccine for the COVID-19 pandemic.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-95086-4","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T06:04:26Z","timestamp":1628057066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice"],"prefix":"10.1038","volume":"11","author":[{"given":"Raife Dilek","family":"Turan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Tastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Dilek Kancagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulut","family":"Yurtsever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Sir Karakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samed","family":"Ozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selen","family":"Abanuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Cakirsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Tumentemur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utku","family":"Seyis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Recai","family":"Kuzay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammer","family":"Elek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyase Ezgi","family":"Kocaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurcan","family":"Ertop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap","family":"Arbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Acikel Elmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Hemsinlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozden","family":"Hatirnaz Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezer","family":"Akyoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilayda","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cavit Kerem","family":"Kayhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Tokat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurler","family":"Akpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Sesin","family":"Kocagoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugur","family":"Ozbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Telci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikrettin","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koray","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siret","family":"Ratip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umit","family":"Ince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercument","family":"Ovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"95086_CR1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science (80-) 369, 77\u201381 (2020).","journal-title":"Science (80-)"},{"key":"95086_CR2","first-page":"2","volume":"1","author":"BL Corey","year":"2020","unstructured":"Corey, B. L., Mascola, J. R., Fauci, A. S. & Collins, F. S. A strategic approach to COVID-19 vaccine R&D. Science 1, 2\u20135 (2020).","journal-title":"Science"},{"key":"95086_CR3","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.csbj.2021.04.061","volume":"19","author":"A Nagy","year":"2021","unstructured":"Nagy, A. & Alhatlani, B. An overview of current COVID-19 vaccine platforms. Comput. Struct. Biotechnol. J. 19, 2508\u20132517 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"95086_CR4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3390\/diagnostics11040579","volume":"11","author":"B Doroftei","year":"2021","unstructured":"Doroftei, B., Ciobica, A., Ilie, O.-D., Maftei, R. & Ilea, C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics 11, 579 (2021).","journal-title":"Diagnostics"},{"key":"95086_CR5","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653 (2017).","journal-title":"Sci. Transl. Med."},{"key":"95086_CR6","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon 3rd","year":"2020","unstructured":"Dinnon, K. H. 3rd. et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560\u2013566 (2020).","journal-title":"Nature"},{"key":"95086_CR7","doi-asserted-by":"publisher","first-page":"281.e6","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281.e6-292.e6 (2020).","journal-title":"Cell"},{"key":"95086_CR8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li, W. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450\u2013454 (2003).","journal-title":"Nature"},{"key":"95086_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"95086_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"S-H Sun","year":"2020","unstructured":"Sun, S.-H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28, 124-133.e4 (2020).","journal-title":"Cell Host Microbe"},{"key":"95086_CR11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"95086_CR12","doi-asserted-by":"crossref","first-page":"e00127-20","DOI":"10.1128\/JVI.00127-20","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127-20 (2020).","journal-title":"J. Virol."},{"key":"95086_CR13","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"95086_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00335-018-9760-9","volume":"29","author":"AS Cockrell","year":"2018","unstructured":"Cockrell, A. S., Leist, S. R., Douglas, M. G. & Baric, R. S. Modeling pathogenesis of emergent and pre-emergent human coronaviruses in mice. Mamm. Genome 29, 367\u2013383 (2018).","journal-title":"Mamm. Genome"},{"key":"95086_CR15","doi-asserted-by":"publisher","first-page":"50.e8","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"R-D Jiang","year":"2020","unstructured":"Jiang, R.-D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50.e8-58.e8 (2020).","journal-title":"Cell"},{"key":"95086_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PBJ McCray","year":"2007","unstructured":"McCray, P. B. J. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"95086_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/CIRCRESAHA.114.300558","volume":"114","author":"X Yang","year":"2014","unstructured":"Yang, X., Pabon, L. & Murry, C. E. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 114, 511\u2013523 (2014).","journal-title":"Circ. Res."},{"key":"95086_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3906\/biy-2004-113","volume":"44","author":"C Ta\u015ftan","year":"2020","unstructured":"Ta\u015ftan, C. et al. SARS-CoV-2 isolation and propagation from Turkish COVID-19 patients. Turk. J. Biol. 44, 192\u2013202 (2020).","journal-title":"Turk. J. Biol."},{"key":"95086_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-83930-6","volume":"11","author":"G Sir Karakus","year":"2021","unstructured":"Sir Karakus, G. et al. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates. Sci. Rep. 11, 1\u201319 (2021).","journal-title":"Sci. Rep."},{"key":"95086_CR20","volume-title":"Genome analysis of SARS-CoV-2 and effects of spike glycoprotein variants on protein structure","author":"OH Ng","year":"2020","unstructured":"Ng, O. H. et al. Genome analysis of SARS-CoV-2 and effects of spike glycoprotein variants on protein structure (2020). (Under revision)"},{"key":"95086_CR21","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/mt.2012.71","volume":"20","author":"G Andolfi","year":"2012","unstructured":"Andolfi, G. et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4+ T cells. Mol. Ther. 20, 1778\u20131790 (2012).","journal-title":"Mol. Ther."},{"key":"95086_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s002510050250","volume":"46","author":"J Eskdale","year":"1997","unstructured":"Eskdale, J., Kube, D., Tesch, H. & Gallagher, G. Mapping of the human IL10 gene and further characterization of the 5\u2032 flanking sequence. Immunogenetics 46, 120\u2013128 (1997).","journal-title":"Immunogenetics"},{"key":"95086_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.7774\/cevr.2015.4.2.145","volume":"4","author":"HS Seo","year":"2015","unstructured":"Seo, H. S. Application of radiation technology in vaccines development. Clin. Exp. Vaccine Res. 4, 145 (2015).","journal-title":"Clin. Exp. Vaccine Res."},{"key":"95086_CR24","doi-asserted-by":"publisher","first-page":"e2074","DOI":"10.1002\/rmv.2074","volume":"29","author":"A Sabbaghi","year":"2019","unstructured":"Sabbaghi, A., Miri, S. M., Keshavarz, M., Zargar, M. & Ghaemi, A. Inactivation methods for whole influenza vaccine production. Rev. Med. Virol. 29, e2074 (2019).","journal-title":"Rev. Med. Virol."},{"key":"95086_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0378-1135(93)90027-5","volume":"37","author":"MS Williams","year":"1993","unstructured":"Williams, M. S. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet. Microbiol. 37, 253\u2013262 (1993).","journal-title":"Vet. Microbiol."},{"key":"95086_CR26","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1016\/j.vaccine.2008.03.095","volume":"26","author":"PH Lambert","year":"2008","unstructured":"Lambert, P. H. & Laurent, P. E. Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?. Vaccine 26, 3197\u20133208 (2008).","journal-title":"Vaccine"},{"key":"95086_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2471\/BLT.10.079426","volume":"89","author":"JK Hickling","year":"2011","unstructured":"Hickling, J. K. et al. Intradermal delivery of vaccines: Potential benefits and current challenges. Bull. World Health Organ. 89, 221\u2013226 (2011).","journal-title":"Bull. World Health Organ."},{"key":"95086_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.tmaid.2019.03.007","volume":"28","author":"F Schaumburg","year":"2019","unstructured":"Schaumburg, F., De Pijper, C. A. & Grobusch, M. P. Intradermal travel vaccinations-when less means more. Travel Med. Infect. Dis. 28, 3\u20135 (2019).","journal-title":"Travel Med. Infect. Dis."},{"key":"95086_CR29","unstructured":"Hickling, J., Jones, R., Nundi, N. & Zehrung, D. Improving the affordability of inactivated poliovirus vaccines (IPV) for use in low- and middle-income countries: An economic analysis of strategies to reduce the cost of routine IPV immunization. PATH, Working in Tandem (2010)."},{"key":"95086_CR30","first-page":"25","volume":"2020","author":"S Jorajuria","year":"2020","unstructured":"Jorajuria, S., Fernandes, M., Vees, M., Dujardin, V. & Regourd, E. Collaborative study for the establishment of the 3rd international standard for amphotericin B. Pharmeuropa Bio Sci. Notes 2020, 25\u201348 (2020).","journal-title":"Pharmeuropa Bio Sci. Notes"},{"key":"95086_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.vaccine.2019.10.080","volume":"38","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. Long-term passage of duck Tembusu virus in BHK-21 cells generates a completely attenuated and immunogenic population with increased genetic diversity. Vaccine 38, 933\u2013941 (2019).","journal-title":"Vaccine"},{"key":"95086_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12887-016-0546-5","volume":"16","author":"R Prymula","year":"2016","unstructured":"Prymula, R., Simko, R., Povey, M. & Kulcsar, A. Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: A randomized, double-blind, non-inferiority trial. BMC Pediatr. 16, 7 (2016).","journal-title":"BMC Pediatr."},{"key":"95086_CR33","first-page":"665","volume":"11","author":"PCY Woo","year":"2004","unstructured":"Woo, P. C. Y. et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin. Diagn. Lab. Immunol. 11, 665\u2013668 (2004).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"95086_CR34","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/s41372-020-00805-w","volume":"41","author":"V Demers-Mathieu","year":"2020","unstructured":"Demers-Mathieu, V. et al. Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM\/IgM, IgG and SIgA\/IgA antibodies in human milk. J. Perinatol. 41, 850\u2013859 (2020).","journal-title":"J. Perinatol."},{"key":"95086_CR35","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","volume":"6736","author":"GA Poland","year":"2020","unstructured":"Poland, G. A., Ovsyannikova, I. G. & Kennedy, R. B. SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates. Lancet (Lond. Engl.) 6736, 1595\u20131606 (2020).","journal-title":"Lancet (Lond. Engl.)"},{"key":"95086_CR36","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1002\/cpmc.108","volume":"58","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr. Protoc. Microbiol. 58, e108\u2013e108 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"95086_CR37","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1128\/JVI.78.7.3572-3577.2004","volume":"78","author":"K Subbarao","year":"2004","unstructured":"Subbarao, K. et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J. Virol. 78, 3572\u20133577 (2004).","journal-title":"J. Virol."},{"key":"95086_CR38","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.amjmed.2021.02.004","volume":"134","author":"FL Hitti","year":"2021","unstructured":"Hitti, F. L. & Weissman, D. Debunking mRNA vaccine misconceptions\u2014An overview for medical professionals. Am. J. Med. 134, 703\u2013704 (2021).","journal-title":"Am. J. Med."},{"key":"95086_CR39","doi-asserted-by":"publisher","first-page":"812.e19","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812.e19-827.e19 (2020).","journal-title":"Cell"},{"key":"95086_CR40","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 11, 6013 (2020).","journal-title":"Nat Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95086-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95086-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:05:51Z","timestamp":1670051151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95086-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95086"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95086-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.28.356667","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]},"assertion":[{"value":"21 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.T., D.D.K., B.Y., G.S.K., S.D., G.T., Dilek Telci, F.S., and E.O. are inventors of patent applications (pending) including \u201cA Method For The Production Of Fast, Inclusive And High-Dose Inactive Vaccine For Use Against SARS-CoV-2 Virus\u201d (2020\/13279) and \u201cA Fast, Inclusive And High-Dose Inactive Method For Adjuvant Positive Vaccination To Be Used Against SARS-CoV-2 Virus\u201d (2020\/14033) at Turkish Patent and Trademark Office. No other author has a competing interest except for these authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15799"}}